The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.
As per IQVIA MAT December 2018 data, the product had annual sales of around USD 76.8 million in the US, Lupin said.
The product is a generic version of Medicis Pharmaceutical Corporation's Solodyn tablets in the same strength, it added.
Shares of Lupin closed at Rs 773.40 per scrip on BSE, down 0.41 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)